We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as lung and colorectal cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.
|Product focus||Blood‐based tests for cancer detection|
|Products on market||Epi proColon®, Epi proLung®|
|R&D pipeline||Multiple projects in cancer detection|
|Technology platform||DNA methylation|
|Patent portfolio||Broad patent portfolio for DNA methylation in cancer|
|IPO||19th July 2004|
|Listing||Frankfurt Stock Exchange, Prime Standard: ECX|
|Location of business||Berlin, Germany (Epigenomics AG)|
Germantown, MD, and Seattle, WA, U.S.A. (Epigenomics Inc.)
|Executive Board||Greg Hamilton, Chief Executive Officer|
Dr. Uwe Staub, Chief Operating Officer
|Supervisory Board||Heino von Prondzynski (Chairman)|
Ann Kessler, Ph.D.
Dr. Helge Lubenow
Prof. Dr. Günther Reiter